OncoMatch/Clinical Trials/NCT07371104
Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer
Is NCT07371104 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including DWZ2501 (Olaparib 150mg) and DWC202510 (Olaparib 150mg) for cancer.
Treatment: DWZ2501 (Olaparib 150mg) · DWC202510 (Olaparib 150mg) — A Multicenter, Open-label, Randomized, Multi-dose, 2-sequence, 2-period, Crossover Bioequivalence Study to Comparison of the Pharmacokinetics and Safety of DWZ2501 and DWC202510 in Patients with Advanced BRCA-mutated High-grade Ovarian Cancer
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 mutation
Required: BRCA2 mutation
Disease stage
Grade: high-grade
advanced high-grade ovarian cancer
Prior therapy
Must have received: PARP inhibitor (olaparib) — maintenance
Subjects who have been maintained on an olaparib dosing regimen of 300 mg (two 150 mg tablets) administered orally twice daily for at least 10 consecutive days
Must have received: PARP inhibitor (olaparib) — maintenance
Subjects who, in the judgment of the principal investigator require a stable dose of olaparib 300 mg (two 150 mg tablets) administered orally twice daily
Cannot have received: radiation therapy
Radiotherapy within 4 weeks prior to screening
Cannot have received: anticancer therapy
Other anticancer therapies within 4 weeks prior to screening
Lab requirements
Liver function
No severe hepatic impairment (Child-Pugh class C)
Severe hepatic impairment (Child-Pugh class C) [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify